Journal
CLINICAL BIOCHEMISTRY
Volume 40, Issue 1-2, Pages 1-5Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.clinbiochem.2006.05.016
Keywords
atorvastatin; high-density lipoprotein (HDL); lecithin : cholesterol acyltransferase (LCAT); cholesteryl ester transfer protein (CETP); paraoxonase (PON)
Categories
Ask authors/readers for more resources
Objectives: The aim of our study was to examine the influence of atorvastatin on lipid parameters, particularly on HDL, and oil the activity of LCAT and CETP and how they affect the activity of the HDL-associated antioxidant enzyme paraoxonase. Design and methods: Thirty-three patients with types II.a and II.b primary hyperlipoproteinemia were enrolled into our study. The patients received atorvastatin, 20 mg daily, for 3 months. We measured the serum paraoxonase activity and concentration, oxidized LDL, LCAT and CETP activities. Results: Atorvastatin significantly reduced the levels of cholesterol, triglyceride, LDL-C and apoB, while it did not influence the levels of HDL-C and apo A-I. The increases in serum PON-specific activity, PON/HDL ratio and LCAT activity were significant, while oxLDL and CETP activities were significantly decreased. Conclusion: Atorvastatin may influence the composition and function of HDL, thereby possibly increasing the activity of paraoxonase and preventing atherosclerosis. (c) 2006 The Canadian Society of Clinical Chemists. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available